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Chapter 3 Reviewing the literature
1. Introduction to reviewing the literature
Systematic reviews are increasingly recognized as an essential step in health care research. They are a method
designed to produce an objective, unbiased, up-to-date summary of available evidence. In this chapter, an outline is
given of the methods used to systematically review the medical literature and to assess the risk of bias in the identified
studies. Results from a systematic review may be summarized as a narrative or a summary estimate produced from a
quantitative meta-analysis. In either case, systematic reviews are usually a necessary step in preparing to conduct
intervention trials and in setting the results of trials into context.
Before embarking on an intervention trial, it is essential to review what is already known about the questions to be
addressed in the trial. The most objective way to do this is to conduct a systematic review of all similar studies that
have been published previously on the topic. Such a review should enable an assessment to be made of whether (1)
sufficient evidence for the effect of the intervention already exists, or (2) there is a clear scientific rationale for an
effect of the intervention, but there is insufficient evidence that the intervention works in practice, or (3) there is an
insufficient rationale for an intervention effect. If the review of the published evidence supports (1) or (3), then there
may be little justification for conducting a (further) trial. Furthermore, funding agencies may require a systematic
review to provide evidence that a new trial is justified, and some journals (including, for example, the Lancet (Clark
and Horton, 2010)) now require authors to include, in papers reporting the results of a trial, a summary of the findings
from a recent systematic review, in order to put their trial into context, or to report their own up-to-date systematic
review. For example, before proposing a trial of a new school-based behaviour change intervention to reduce the
incidence of HIV infection, it would be essential to review the literature on the effectiveness of previous school-based
interventions, and also to review the literature on the rationale underpinning the mechanism by which such an
intervention might be expected to be effective.
A proposed trial is worthwhile if the conclusions from a systematic search of the literature provide a strong rationale
that the proposed intervention will work, but there is currently insufficient evidence to know how effective, if at all, it
is likely to be in the target population for the trial. In addition to wasting time and resources, a trial of an intervention
which has already been proven effective may be considered unethical, as participants in the control arm would not
receive a beneficial intervention, and conducting a further trial may delay scale-up of the intervention to those who
would benefit from it.
In this chapter, we describe methods for conducting systematic reviews of epidemiological studies (including
observational studies as well as intervention trials) to judge whether a new intervention trial is justified. We also
include sections on assessing the risk of bias in studies and on providing a narrative and quantitative summary of the
findings.
Systematic reviews are not trivial undertakings, and not all investigators will have the time or resources to conduct the
kind of review that we outline in this chapter. Ideally, other investigators will have conducted a recent review, and it
will be possible to utilize their findings. For example, an agency such as the World Health Organization (WHO) might
have commissioned a review in order to assist them in setting priorities for disease control or to highlight important
areas for research. Those planning to conduct a trial might not need to conduct their own systematic review but could
build on the previous work. However, even if an investigator is not going to undertake their own review, it is
important that they understand how such reviews are conducted and indeed can assess the quality of published
systematic reviews. This chapter should facilitate this.
The insights that a systematic review can give to the reviewers on the effects of an intervention and the quality of
previous studies are invaluable. It is highly recommended that all those conducting trials participate in at least one
systematic review fairly early in their careers!
2. Systematic reviews
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Reviewing the literature can be a daunting task. The volume of information available through published papers, or the
Internet, is vast and constantly expanding. Given the volume of literature available, an ‘ad hoc’ review of the
literature is subject to substantial biases if only some studies are included, since the studies that are found this way
may well not be representative of all the relevant studies. The best way to ensure an objective and unbiased review of
the literature is to conduct a review that follows strict guidelines to minimize bias in selecting and interpreting
reported studies.
The basic steps in a systematic review are shown in Box 3.1.
In this chapter, we provide a brief overview of each of these steps. Further details are given in published guidelines,
such as the Cochrane handbook for systematic reviews of interventions (Higgins and Green, 2008) and the PRISMA
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (<http://www.prisma-
statement.org>) (Liberati et al., 2009), and books on systematic reviews in health research (Egger et al., 2001,
Glasziou, 2001, Khan, 2003).
2.1. Defining the question
The first step in a systematic review is to define the research question. A structured approach for framing the question
is useful—the PICOS approach (Population; Interventions (or Exposure); Comparison; Outcomes; Study design)
(Higgins and Green, 2008) is used by both Cochrane and PRISMA.
For example, a systematic review summarized the evidence of the effectiveness of behavioural interventions to
prevent HIV infection among young people in sub-Saharan Africa (Napierala Mavedzenge et al., 2011). The review
question was structured, using the PICOS approach, as follows:
Population: Among young people aged 10–24 years in sub-Saharan Africa . . .
Intervention/exposure/comparison: . . . does exposure to an intervention focusing on reducing HIV risk
behaviours, relative to no or minimal intervention, . . .
Outcomes: . . . reduce the risk of HIV, STIs, or pregnancy . . .
Study design: . . . when evaluated through experimental or quasi-experimental study designs?
A second example, used in this chapter, is a systematic review of the evidence that the use of chewing substances
(such as smokeless tobacco or betel nuts) is associated with cardiovascular disease (CVD) in Asia (Zhang et al.,
2010). In this case, the question was structured as follows:
Population: Among people in Asian countries . . .
Intervention/exposure/comparison: . . . does exposure to chewing substances, relative to not chewing them, . . .
Outcomes: . . . increase the risk of CVD . . .
Study design: . . . when evaluated through observational epidemiological studies?
Previous systematic reviews had examined this question in the United States of America (USA) and Sweden, but
there was no synthesis of the evidence from Asia. If strong evidence for an association was found, this could lead to
the development and evaluation of an intervention directed at reducing betel chewing in these populations.
Once the research question is identified, a detailed protocol should be prepared for the review. This will include
definition of the search strategy and the planned analyses. There are plans to develop an international register of
systematic reviews, led by the Centre for Reviews and Dissemination (<http://www.york.ac.uk/inst/crd/index.htm>),
which will enable researchers to register their review protocol. This will extend the register developed by the
Cochrane Collaboration (<http://www.cochrane.org>), which was established in 1993 to promote systematic reviews
of health care interventions. Researchers undertaking reviews under the Cochrane Collaboration are required to
register the protocol for their review in advance, and the review is peer-reviewed before publication. However, many
systematic reviews are undertaken outside of the Collaboration and may not currently be registered.
2.2. Identifying relevant literature
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The most time-consuming step of a systematic review is to identify studies which address the defined review
question. The aim is to have a search strategy which is highly sensitive (i.e. there is a very high probability of
including relevant studies), specific (i.e. there is a high probability of excluding non-relevant studies), and precise (i.e.
the proportion of studies retrieved which are relevant is high) (Jenkins, 2004).
The first step in defining the search strategy to identify published papers is to set inclusion and exclusion criteria,
based on the review question (Table 3.1). Ideally, searches should include papers published in any language (to be
fully inclusive and to avoid possible publication bias of those with positive findings being more likely than those with
negative findings to be published in English language journals). RCTs are generally regarded as the gold standard for
providing evidence of the impact of an intervention, and it is essential to review previous RCTs of similar
interventions. However, if there have been few relevant RCTs, non-randomized trials and observational studies should
also be reviewed. The initial search may be limited to published papers, but sometimes it is important to include the
‘grey’ literature (conference abstracts, technical reports, and discussion papers). This is because some completed
studies are never published in peer-reviewed journals, and studies are often less likely to be published there if they do
not find an effect of the intervention. Inclusion of unpublished studies may therefore reduce bias. However,
unpublished studies are difficult to identify and have not undergone peer review, so they may be of poorer quality and
insufficient information may be provided to contribute usefully to a review.
2.2.1. Electronic searching
Three commonly used electronic medical databases are MEDLINE (available freely via PubMed at
<http://www.ncbi.nlm.nih.gov/PubMed>), Embase (<http://www.embase.com>), and CENTRAL (Cochrane Central
Register of Controlled Trials, <http://www.cochrane-handbook.org>). A comprehensive search strategy requires each
of these databases to be searched (Higgins and Green, 2008). However, these databases have a North
American/European bias, and, for studies in LMICs, it is worth also searching other relevant databases such as
LILACS (Latin American Caribbean Health Sciences Literature), African Healthline, GlobalHealth, and Popline. In
addition, there are many subject-specific databases, such as PsychInfo (for psychology and related behavioural and
social sciences), as well as Internet search engines such as Google Scholar. It may also be useful to search conference
databases and trial registries to identify additional papers.
Strategies can be used to identify both free-text words in the database and controlled terms (called MeSH in
MEDLINE, i.e. medical subject headings) that are used as keywords. Search strategies need to include the key terms
in the review question and use the Boolean operators (such as ‘AND’, ‘OR’, ‘NOT’) to produce a search that is both
sensitive and specific to the research question. The search strategy used for the example of chewing substances and
CVD in Asia is given in Box 3.2.
Often the reviewers will already know about some key published studies. It is useful to check that all of these have
been identified by the electronic database search. If not, a careful review of the search strategy may establish the
reason for this, and the search can be amended accordingly.
2.2.2. Reviewing abstracts
The search strategy commonly identifies several thousands of potentially relevant papers. The next step is for two
reviewers to independently read through the abstract of each paper and define it as being potentially relevant or not.
At this stage, it is recommended to err on the side of caution, i.e. include as ‘potentially relevant’ if the relevance is
unclear from the abstract. The two reviewers should then compare their results and reconcile any differences by
discussion, further reference to the abstracts, or a third reviewer independently reading the abstract.
2.2.3. Reviewing full articles
Full copies of all papers, the abstracts of which were considered to be potentially relevant, should be obtained
(electronically, from libraries, or by emailing the author). They should be reviewed by the two reviewers who
independently assess whether or not each paper meets each of the inclusion/exclusion criteria. Discrepancies should
be resolved as for the abstracts.
2.2.4. Hand searching
The next step in the search strategy is usually to review the reference lists of all the eligible studies identified from the
electronic database search, to identify any studies that were missed by that search but have been referenced in the
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eligible papers.
Previous review papers should also be read to check that no known papers have been omitted. Finally, it is legitimate,
though sometimes time-consuming, to include unpublished studies which can be identified through colleagues or
contact with the investigators of unpublished studies, for example, identified through Internet searches or trial
registers. It is also important to identify ongoing studies, where possible, as these may be included in updates of the
review.
2.2.5. Flow chart of search strategy
The template for a flow chart summarizing the search results is given in Figure 3.1. In the example of behavioural
interventions among young people in sub-Saharan Africa, a total of 1173 papers were identified from the electronic
databases, of which 137 were deemed potentially relevant after review of their titles and abstracts, and full-text
articles were obtained. After excluding those not meeting the inclusion criteria, the final review included 40 papers,
representing 23 studies (as sometimes the results of one study were reported in more than one paper) (Napierala
Mavedzenge et al., 2011). For the example of chewing substances and CVD in Asia, 1756 publications were
identified from electronic databases, of which only six were eligible for inclusion in the analysis of CVD (Zhang et
al., 2010).
2.3. Descriptive synthesis of studies
When the eligible papers have been identified, a data extraction form should be completed for each study, which
contains fields enabling a detailed description of the study design and of the results. For example, descriptive
elements would include the PICOS components, as discussed in Section 2.1. The results should focus on the pre-
specified outcomes in the review protocol and would include outcome measures, definition of
exposures/interventions, measures of effect, and 95% confidence intervals (CIs). The form should be pilot-tested on a
few sample papers and revised, as appropriate. Two reviewers then read each paper in detail independently,
summarize the paper on to the data extraction form, and appraise the risk of biases. A common shortcut, which is
permissible, is that one reviewer completes the data extraction form and the other then checks and edits it, with the
final version based on a discussion of any discrepancies.
The next step is to begin to summarize the evidence from the eligible studies as a whole. All reviews should include a
descriptive table of the included studies, which summarize the study population, intervention, comparison, outcome,
and study design. One of the 23 studies that were identified in the review of behavioural interventions among young
people is summarized in Table 3.2.
In the table that summarizes the results of each study, all the primary and secondary outcome measures should be
included. For a binary outcome, this would include the proportion with the outcome among the exposed and
unexposed groups, the appropriate measure of effect (e.g. risk ratio (RR), rate ratio (RR), or odds ratio (OR)), and
95% CI. For continuous outcomes, the mean, standard deviation in the exposed and unexposed, plus the effect
measure (e.g. standardized mean difference) should be given.
2.4. Assessing risk of bias in the studies
Once the description of each study is completed, an evaluation should be conducted of the extent of potential bias and
error that may have arisen, either from the design or the analysis of each of the original studies. The main aim of this
is to guide interpretation of the findings of the review. In some cases, it may be decided to exclude a study which is
flawed to the extent that the results are considered likely not to be valid. Alternatively, a sensitivity analysis might be
conducted to evaluate how the summary results differ if results from more flawed studies are included or excluded.
There are several methods for assessing the risk of bias, including checklists or ‘quality score’ scales. The
recommendation of the Cochrane Collaboration and the PRISMA guidelines is to use a ‘domain-based evaluation’, in
which critical assessments are made for domains such as blinding of participants and generation of the random
sequence (for randomized studies) (Higgins and Green, 2008). For observational studies, there are additional possible
sources of bias. For example, in case-control studies, check should be made on the external validity of case selection,
the choice of control group, and adjustment for confounding factors.
Table 3.3 summarizes some of the sources of potential bias in RCTs and observational studies.
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The assessment of potential biases should be tailored to the research question. For each review, there should be
consideration of whether one potential bias is more important to the interpretation of findings than others. For
example, if an outcome is measured objectively (for example, mortality), then blinding of those evaluating the
outcome is not going to be very important. In contrast, if loss to follow-up is high and associated with the outcome,
then this could cause substantial bias.
A table summarizing the risk of bias in each study should be completed independently by two reviewers, and any
differences reconciled by discussion or reference to a third reviewer. Summarizing the results can be done in different
ways—some authors rank the studies in order of quality; others divide them into those with low, medium, or high risk
of bias. These decisions should be taken independently of the results of the studies, if possible, before examining the
results, and the reviewers need to decide which studies (if any) will be taken forward to a quantitative meta-analysis
of findings.
2.5. Quantitative synthesis of results
2.5.1. Forest plots
Following the descriptive analysis and assessment of risk of bias, it may or may not be appropriate to conduct a
formal meta-analysis that quantifies the overall effect of the intervention. If, for example, the study populations,
interventions, and reported outcomes differed substantially, the authors may decide to focus on describing the studies,
their results, applicability, and limitations in a narrative review, rather than produce a quantitative summary. This was
the case for the systematic review of interventions in young people in sub-Saharan Africa (Napierala Mavedzenge et
al., 2011).
In other cases, it might be useful to summarize the data quantitatively. A first step for this is to produce a graph, called
a forest plot, which displays the measure of effect (e.g. OR) for each study, together with a horizontal line denoting
the CI. Before constructing such a graph, it is important to consider whether the results from the different studies are
indeed measuring the same effect and are comparable to each other. For example, a smoking cessation intervention
may have a different effect in pregnant women than among teenage girls. In such cases, it would be beneficial to
present results stratified by subgroups, in whom effects might be expected to differ. As with all analyses, these
subgroups should be defined in advance and included in the review protocol. For example, in the review of chewing
substances in Asia, it was decided a priori to stratify by geographical region, to minimize confounding due to the
presence or absence of tobacco in chewing substances, as this was thought to differ between regions.
In this example, the six eligible studies included five cohort studies and one case-control study. The forest plot is
shown in Figure 3.2. The solid vertical line indicates a relative risk (RR) of one, representing no association between
the exposure and outcome. In this example, all six studies had a RR greater than one, indicating an increased risk of
CVD among individuals who used chewing substances, and the 95% CI did not include one for four of these studies,
indicating strong evidence of an association. The forest plot also includes an overall (summary) estimate of the RR.
This is a weighted average of the effects from each of the studies.
There are two main methods of obtaining the summary measure of an intervention effect. In a ‘fixed-effects’ model, it
is assumed that the true effect of exposure (or the intervention) is the same in each study, any variation between
studies being solely due to chance. In contrast, a ‘random-effects’ model may be used, in which the true effect of
exposure for the individual studies are assumed to inherently vary (e.g. due to differences in the populations or
residual confounding factors). In a random-effects model, the weights allow for this between-study variation, as well
as the random variation.
In Figure 3.2, a random-effects model was used, and the weights for each study are given on the right-hand side of the
forest plot. The overall (summary) estimate is RR = 1.26, with a 95% CI of 1.12–1.40. Note that this summary
estimate is more precise (i.e. has a narrower CI) than any one of the individual studies. By undertaking a systematic
review and meta-analysis, the reviewers can now report that there is strong evidence that, in these populations,
exposure to chewing substances was associated with an increased risk of CVD of around 26%, compared with non-
users.
2.5.2. Examining heterogeneity
The effect sizes of individual studies will inevitably be different from each other, but it is important to assess whether
this difference is likely to be due to random variation (i.e. the true underlying effect will be the same) or to real
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differences in underlying effect sizes in the individual studies. It is therefore essential to examine the consistency of
the effects and to quantify the heterogeneity (or difference) in effect sizes between studies. Several measures are
available for this, one of which is the I  statistic (Higgins et al., 2003). This statistic is the percentage of total variation
across studies that is due to heterogeneity, rather than chance. A value of I  of 0% indicates no observed
heterogeneity, and larger values indicate increasing heterogeneity. The principal advantage of the I  statistic is that it
does not depend on the number of studies included in the meta-analysis and so can be used even for meta-analyses
containing relatively few studies, which typically have low power to detect heterogeneity using other measures.
In our example, the value of I  is 35.9%, with a p-value of 0.17, indicating little evidence of heterogeneity. The
reviewers were therefore justified in presenting the summary estimate. If, in contrast, the I  statistic suggests evidence
of heterogeneity, for example if I  was 70%, further exploration of the causes of heterogeneity would be needed, for
example by undertaking (pre-specified) subgroup analyses. If there was no longer evidence of heterogeneity within
subgroups, this would indicate that the stratifying characteristics were an important source of heterogeneity, and
results should be presented within subgroups, rather than overall.
3. Software available for systematic reviews and meta-analyses
Systematic reviews involve managing large quantities of information. There are various software packages available
which can be used to prepare systematic reviews. For example, the Cochrane Collaboration produces a freely
available program called RevMan which is a Windows-based software package designed to enter reviews in the
Cochrane format. This includes an analysis module (MetaView) for quantitative summaries.
Results of searches from electronic databases can also be automatically downloaded into a reference manager
software package, such as EndNote, and, from there, exported into database packages, such as Excel, for review and
assessment of abstracts. Standard statistical packages, such as Stata, include modules for meta-analyses.
4. Reporting findings from systematic reviews
There are several guidelines for reporting results of a systematic review. The most recent are the PRISMA guidelines
(<http://www.prisma-statement.org>) which are given in Table 3.4 (Moher et al., 2009). These include a full
description of the rationale for the review, the research question, methods used, and analyses. Reviewers will then
need to summarize their main findings, including the strengths and limitations of the review, the strength of the
evidence for each main outcome, and the relevance to different population groups.
Finally, the results of the systematic review need to be assessed for their implications for policy and future research.
One system to assist with interpreting results of systematic reviews is the GRADE system (Grading of
Recommendations Assessment, Development, and Evaluation) (Guyatt et al., 2008). This gives guidelines as to
whether results from a systematic review provide ‘strong’ or ‘weak’ evidence. This includes not only results of a
systematic review, but also an evaluation of the balance between desirable and undesirable effects, and whether the
intervention represents a wise use of resources.
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Flow diagram of study selection process.
From Moher et al., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,
PLoS Medicine, Volume 6, Issue 7, e1000097, Copyright © Moher et al. 2009. This figure is reproduced from an
open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are
credited.
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Figure 3.2
Forest plot for the association of exposure to chewing substances and risk of CVD in Asia.
Reproduced from Zhang, L. N. et al., Chewing substances with or without tobacco and risk of cardiovascular
disease in Asia: a meta-analysis, Journal of Zhejiang University Science B, Volume 11, Issue 9, pp. 681–9,
Copyright © Zhejiang University and Springer-Verlag Berlin Heidelberg 2010, with permission from Springer and
Springer Science and Business Media. This image is not covered by the Creative Commons licence terms of this
publication. For permission to reuse please contact the rights holder.











Table 3.1 Inclusion criteria: example for the systematic review of behavioural interventions to
prevent HIV infection among young people in sub-Saharan Africa
PICOS component
(see text)
Inclusion criteria Exclusion criteria
Population Young people aged 10–24 years. In studies with a wider
age range, there must be an analysis of the impact of the
intervention in young people (10–24 years) or, at least, in
part of that age range.
In sub-Saharan Africa.
Based in a school, and/or health facility, and/or
geographically defined community.
Study population not
representative of a general
population of young people (for
example, young sex workers).
Fewer than 100 people in the
study.
Intervention/exposure Behavioural intervention focused on one or more of the
following:
improving sexual and reproductive health skills and
behaviour
reducing the risk of sexually transmitted diseases
(STDs)
reducing unintended pregnancies
increasing utilization of health services for treatment
of STIs and/or behaviours related to more
appropriate service utilization.
Comparison No or minimal behavioural intervention. No suitable comparison group
(for example, non-randomized
study with post-intervention data
only).
No adjustment for differences
between groups that might bias
the findings.
Outcome At least one of the following measured:
prevalence or incidence of HIV infection
prevalence or incidence of another STI
prevalence or incidence of pregnancy (measured by
laboratory test or clinically observed)
reported sexual and reproductive health behaviour
(including treatment-seeking behaviour).
Measured less than 3 months
after the intervention starts.
Study design Published in 2005–2008 (because an earlier systematic
review had covered the period up to the end of 2004).
Randomized and non-randomized epidemiological studies
which included a contemporaneous comparison group or a
before–after/time series analysis in the intervention group
only.
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Table 3.2 Description of one of the studies included in the systematic review of youth







Target population, primary objectives,





























Persons aged 12–19 years in rural areas.
Primary objectives:
Delayed sexual initiation, increased
condom use, decreased number of sexual
partners, and increased use of health
services, especially for sexual and
reproductive health services.
Comparison arm:
Current (very limited) sexual and
reproductive health education in schools,
and no additional interventions within
health facilities or in the wider community.
Study outcomes:
Primary: HIV incidence; HSV2
prevalence.
Secondary: pregnancy (by test and self-
reported); prevalence of other STIs (by test
and self-reported); knowledge and attitudes
related to sexual and reproductive health
issues; self-reported sexual risk behaviours,
including sexual debut during trial follow-
up, use of condoms, number of sexual






















Ten to 15 lessons per









Adapted with permission from Journal of Adolescent Health, Volume 49, Issue 6, Napierala Mavedzenge et al., HIV prevention in young
people in sub-Saharan Africa: a systematic review, pp. 568–86, Copyright © 2011 Society for Adolescent Health and Medicine. Published
by Elsevier Inc. All rights reserved. <http://www.sciencedirect.com/science/journal/1054139X>. This table is not covered by the Creative
Commons licence terms of this publication. For permission to reuse please contact the rights holder.
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Assessment for observational studies
Selection
bias










Systematic differences in the care











Systematic differences between the







Differing follow-up rates between exposed




Systematic difference in outcome
assessment
Blinding of those evaluating outcome
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Table 3.4 PRISMA guidelines for systematic reviews and meta-analyses








2 Provide a structured summary, including, as applicable: background; objectives; data
sources; study eligibility criteria, participants, and interventions; study appraisal and
synthesis methods; results; limitations; conclusions and implications of key findings;
systematic review registration number
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of what is already known
Objectives 4 Provide an explicit statement of questions being addressed with reference to




5 Indicate if a review protocol exists, if and where it can be accessed (for example, Web




6 Specify study characteristics (for example, PICOS, length of follow-up) and report
characteristics (for example, years considered, language, publication status) used as
criteria for eligibility, giving rationale
Information
sources
7 Describe all information sources (for example, databases with dates of coverage,
contact with study authors to identify additional studies) in the search and date last
searched
Search 8 Present full electronic search strategy for at least one database, including any limits
used, such that it could be repeated
Study
selection
9 State the process for selecting studies (i.e. screening, eligibility, included in systematic




10 Describe method of data extraction from reports (for example, piloted forms,
independently, in duplicate) and any processes for obtaining and confirming data from
investigators
Data items 11 List and define all variables for which data were sought (for example, PICOS, funding




12 Describe methods used for assessing risk of bias of individual studies (including
specification of whether this was done at the study or outcome level) and how this
information is to be used in any data synthesis
Summary
measures
13 State the principal summary measures (for example, risk ratio, difference in means)
Synthesis of
results
14 Describe the methods of handling data and combining results of studies, if done,
including measures of consistency (for example, I ) for each meta-analysis
Risk of bias
across studies
15 Specify any assessment of risk of bias that may affect the cumulative evidence (for
example, publication bias, selective reporting within studies)
Additional
analyses
16 Describe methods of additional analyses (for example, sensitivity or subgroup
analyses, meta-regression), if done, indicating which were pre-specified
RESULTS
2
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17 Give numbers of studies screened, assessed for eligibility, and included in the review,
with reasons for exclusions at each stage, ideally with a flow diagram
Study
characteristics
18 For each study, present characteristics for which data were extracted (for example,
study size, PICOS, follow-up period), and provide the citations
Risk of bias
within studies
19 Present data on risk of bias of each study and, if available, any outcome level




20 For all outcomes considered (benefits or harms), present, for each study: (a) simple
summary data for each intervention group, (b) effect estimates and confidence
intervals, ideally with a forest plot
Synthesis of
results




22 Present results of any assessment of risk of bias across studies (see item 15)
Additional
analysis
23 Give results of additional analyses, if done (for example, sensitivity or subgroup




24 Summarize the main findings, including the strength of evidence for each main
outcome; consider their relevance to key groups (for example, health care providers,
users, and policy makers)
Limitations 25 Discuss limitations at study and outcome level (for example, risk of bias) and at
review level (for example, incomplete retrieval of identified research, reporting bias)
Conclusions 26 Provide a general interpretation of the results, in the context of other evidence, and
implications for future research
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (for example,
supply of data); role of funders for the systematic review
From Moher et al., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Medicine, Volume 6,
Issue 7, e1000097, Copyright © Moher et al. 2009. This table is reproduced from an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.








Box 3.1 The five basic steps in a systematic review
Defining the question.
Identifying relevant studies in a predefined, systematic way.
Assessing the quality of each relevant study.
Summarizing the evidence.
Interpreting the findings.
Box 3.2 Example of a search strategy for evidence of an association between chewing
substances and CVD, ischaemic heart disease, or cerebrovascular disease in Asia
We searched PubMed (up to July 2010), using the terms: (‘cardiovascular diseases’ [MeSH] OR
(‘cardiovascular’ [All Fields] AND ‘diseases’ [All Fields]) OR ‘cardiovascular diseases’ [All Fields] OR
‘cerebrovascular disorders’ [MeSH] OR (‘cerebrovascular’ [All Fields] AND ‘disorders’ [All Fields]) OR
‘cerebrovascular disorders' [All Fields] OR ‘stroke’ [MeSH] OR ‘stroke’ [All Fields] OR 'mortality' OR death*)
AND (‘betel quid’ OR ‘betel-quid’ OR ‘betel nut’ OR ‘betel nuts’ OR ‘areca nut’ OR ‘areca nuts’ OR ‘paan’ OR
‘pan’ OR 'snuff' OR 'snus' OR ‘gul’ OR ‘gutka’ OR ‘khaini’ OR ‘loose leaf’ OR ‘maras’ OR ‘mawa’ OR
‘mishri’ OR ‘naswar’ OR ‘Areca catechu’ OR ‘tooth powder’ OR ‘shammah’ OR ‘tobacco chewing gum’ OR
‘zarda’ OR ‘tobacco, smokeless’ [MeSH] OR ‘smokeless tobacco’ OR ‘chewing tobacco’ OR ‘non-smoking
tobacco’) AND (‘cohort studies’ [MeSH] OR ‘cross-sectional studies’ [MeSH] OR ‘case control studies’
[MeSH] OR (‘cohort’ [TI] AND stud* [TI]) OR (case* [TI] AND control* [TI]) OR 'prospective' OR
'retrospective' OR 'cross-sectional' OR ‘cross sectional’), which yielded 1006 potentially relevant references. We
adapted the searching strategy for a second search in ISI Web of Science (updated 19 July 2010) and found
another 739 references. We identified all observational studies, including cohorts, case-control studies, and cross-
sectional studies, provided that they explored the association between ever using chewing substances and the
occurrence (incidence or mortality) of CVD and reported the strength of the associations with a quantitative risk
estimate. There was no limitation on the language, study year, or publication status.
Text extract reproduced from Zhang, L. N. et al., Chewing substances with or without tobacco and risk of
cardiovascular disease in Asia: a meta-analysis, Journal of Zhejiang University Science B, Volume 11, Issue 9,
pp.681–9, Copyright © Zhejiang University and Springer-Verlag Berlin Heidelberg 2010. This box is not
covered by the Creative Commons licence terms of this publication. For permission to reuse please contact the
rights holder.
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